- Following completion of the initial phase of its collaboration with OmniAb, VERAXA will engineer the final VXA-222 candidate and conduct the preclinical validation needed to determine the program’s next development steps.
- VXA-222 uses an “AND-gate” approach designed to recognize two tumor-associated antigens simultaneously before delivering its therapeutic payload.
- The company has separately filed its first patents related to its BiTAC-TCE and BiTAC-ADC platforms while expanding protection around antibody conjugation and payload technologies.
- The company is building a diversified oncology pipeline spanning bispecific T-cell engagers, ADCs, and other engineered antibody formats.
VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has moved its VXA-222 bispecific antibody-drug conjugate program into the next stage of development after completing the initial phase of its collaboration with OmniAb, giving the biotechnology company a new development milestone while it continues expanding the intellectual-property estate underpinning its antibody technology portfolio.
According to a Yahoo Finance report, VERAXA will now take the antibody binders generated through the OmniAb collaboration and use its own antibody engineering, linker and conjugation technologies to construct the final VXA-222 candidate. The company will then conduct in vitro and in vivo studies as part of the preclinical validation process (https://ibn.fm/jR6JV).
The development update comes as VERAXA pursues a broader oncology strategy that includes antibody-drug conjugates, T-cell engagers and engineered antibody formats. VERAXA’s corporate materials outline a technology-focused approach to antibody therapeutics, with the company developing programs both around its proprietary BiTAC platform and through other antibody-engineering technologies.
The VXA-222 program originated from a collaboration with OmniAb that began in May 2025. Under the arrangement, OmniAb applied its antibody-discovery capabilities to generate therapeutic antibody binders suitable for development into a bispecific ADC.
OmniAb’s contribution included its OmniClic(TM) transgenic chicken technology, which is designed to generate common-light-chain antibodies that can be used in bispecific therapeutics. The discovery program produced a portfolio of human antibody candidates that underwent affinity maturation.
With that phase completed, responsibility for the next stage shifts to VERAXA. The company plans to combine the selected binders with its proprietary antibody engineering, linker and conjugation technologies. The objective is to produce the final bispecific antibody-drug conjugate candidate and then evaluate its performance through laboratory and animal studies.
VXA-222 is designed around an “AND-gate” mechanism. Instead of relying on recognition of a single tumor-associated antigen, the bispecific molecule is intended to recognize two separate targets simultaneously. The rationale is that requiring both targets to be present could increase selectivity for cancer cells while reducing exposure to healthy tissue.
The VXA-222 milestone coincides with another area of activity that is particularly relevant to a development-stage biotechnology company: intellectual property. On July 29, VERAXA announced its first patent filings covering its newest BiTAC technology platforms, including BiTAC-TCE and BiTAC-ADC programs.
The filings cover more than individual drug candidates. According to the company, the applications include composition-of-matter claims, proprietary payload technologies and elements of the underlying antibody-engineering platforms. Additional intellectual-property work covers enabling technologies such as click chemistry and conjugation methods. VERAXA said certain patent applications involving these technologies have also completed their opposition periods.
The company now reports more than 50 granted patents that it either owns or exclusively licenses, spanning 26 patent families in 14 countries. Newly filed applications, if ultimately granted, are expected to extend protection for portions of its technology portfolio through at least 2047.
A significant portion of the company’s intellectual-property strategy is focused on its BiTAC platform. VERAXA describes BiTAC as a molecular architecture designed to increase tumor selectivity through dual-target recognition. The underlying concept is to require interaction with two cancer-associated targets before the therapeutic mechanism becomes active.
The company’s BiTAC-TCE approach applies this concept to T-cell engagers. The BiTAC-TCE approach splits a TCE into two complementary antibody components whereby each component alone retains the ability to bind its tumor target, but its CD3-engaging activity remains switched off. Full cytotoxic activity is triggered only when both components co-localize on a single cell, meaning a cancer cell that expresses both intended target antigens.
Its BiTAC-ADC approach uses two antibody components that independently deliver inactive components, which are intended to become therapeutically active through a specific click-to-release chemical reaction inside targeted tumor cells.
These approaches are being developed with the goal of limiting activity outside tumors while addressing technical considerations associated with conventional antibody-based therapies.
The broader antibody-drug conjugate market has attracted substantial pharmaceutical investment because ADCs combine the targeting properties of antibodies with potent therapeutic payloads. Bispecific formats add another layer by allowing a therapy to recognize multiple biological targets.
VERAXA’s strategy is therefore not dependent on a single molecular format. The company’s pipeline includes conventional and bispecific ADC programs alongside T-cell engagers and other engineered antibody candidates.
For more information, visit the company’s website at www.Veraxa.com.
NOTE TO INVESTORS: The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA
About BillionDollarClub
BillionDollarClub (“BDC”) is a specialized communications platform with a focus on the biggest and brightest companies covered by IBN. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BDC is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists, and the general public. By cutting through the overload of information in today’s market, BDC brings its clients unparalleled recognition and brand awareness.
BDC is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BillionDollarClub, text “Billion” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BillionDollarClub.com
Please see full terms of use and disclaimers on the BillionDollarClub website applicable to all content provided by BDC, wherever published or re-published: https://www.BillionDollarClub.com/Disclaimer
BillionDollarClub
Los Angeles, CA
www.BillionDollarClub.com
310.299.1717 Office
Editor@BillionDollarClub.com
BillionDollarClub is powered by IBN
